Stelara is a biologic that was approved for the treatment of psoriasis in 2009 and for the treatment of psoriatic arthritis in 2013.

What is Stelara?

Stelara (also known by its generic name ustekinumab) was approved by the FDA in September 2009 for the treatment of moderate-to-severe plaque psoriasis in patients ages 6 years and older. In September 2013 the FDA also approved Stelara to treat adults with active psoriatic arthritis.

Stelara is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.

To learn more, please visit the Stelara website.

A mother and child lay in a tent and read a book together.

FDA Approves Stelara® for Pediatric Psoriasis Patients

The FDA has approved the use of Stelara® (ustekinumab) for use in pediatric patients.

Learn more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.